Titlebook: Rough Sets; International Joint Andrea Campagner,Oliver Urs Lenz,JingTao Yao Conference proceedings 2023 The Editor(s) (if applicable) and

航天飛機

書目名稱Rough Sets影響因子(影響力)




書目名稱Rough Sets影響因子(影響力)學科排名




書目名稱Rough Sets網(wǎng)絡公開度




書目名稱Rough Sets網(wǎng)絡公開度學科排名




書目名稱Rough Sets被引頻次




書目名稱Rough Sets被引頻次學科排名




書目名稱Rough Sets年度引用




書目名稱Rough Sets年度引用學科排名




書目名稱Rough Sets讀者反饋




書目名稱Rough Sets讀者反饋學科排名

臨時抱佛腳

Phenothiazines

An Acceleration Method for?Attribute Reduction Based on?Attribute Synthesisw decision system can be formed by all the pseudo-attributes. Thirdly, the pseudo-attribute with the greatest importance is selected through the forward greedy search strategy in the new decision system. Finally, let the original attributes corresponding to the selected pseudo-attribute be an attrib

北極人

Attribute Reduction Based on the Multi-annulus Model attribute added to the attribute reduction pool, the forward greedy strategy is employed. Its essence is to divide the unevenly distributed data into corresponding annuluses and reduce the preprocessing process of the data itself, so as to accelerate the process of attribute reduction. Compared wit

子女

Deterministic and?Nondeterministic Decision Trees for?Decision Tables with?Many-Valued Decisions froon trees on the complexity of the set of attributes attached to columns. We enumerate all types of behavior of these functions. We also study the dependence in the worst case of the minimum complexity of deterministic decision trees on the minimum complexity of nondeterministic decision trees. This

opprobrious

Kryszkiewicz’s Relation for?Indiscernibility of?Objects in?Data Tables Containing Missing Valuesbetween the two approaches, we propose another relation for indiscernibility that is equal to the intersection of possible indiscernibility relations. By using Kryszkiewicz’s relation and the proposed relation, Kryszkiewicz’s approach can derive the same approximations as Lipski’s one. Therefore, we

Redundant

nonplus

治愈

products which have been found to be appropriate for a specific medical device are labeled “biomaterials” (or more modestly, materials for medical use) on the grounds of established specifications and quality control, supported by continuing feedback from the clinical experience. The major obstacle

NAV

products which have been found to be appropriate for a specific medical device are labeled “biomaterials” (or more modestly, materials for medical use) on the grounds of established specifications and quality control, supported by continuing feedback from the clinical experience. The major obstacle